Glenn J. Lesser, MD
- Professor, Hematology and Oncology

Glenn J. Lesser, MD
Research Interests
- Glioma
- Glioblastoma
- Low-Grade Glioma
- Clinical Trials
- Neuro-Oncology
- Brain Tumors
- Education
- BA, Duke University, 1983
- MD, Pennsylvania State University College of Medicine, 1987
- Residency
- Wake Forest Baptist Medical Center, 1988
- Wake Forest Baptist Medical Center, 1990
- Fellowship
- Johns Hopkins Hospital, 1994
- Board Certifications
- American Board of Internal Medicine, Medical Oncology
- Memberships
- American Society of Clinical Oncology
- American Medical Association
- Southern Medical Association
- American College of Physicians Fellow
- Society of Neuro-Oncology
- Southern Association For Oncology
- North Carolina Medical Association
- Positions
- Louise McMichael Miracle Professorship in Oncology
Professor, Hematology and Oncology - Professor, Neurosurgery
- Professor, Public Health Sciences
- Professor, Anesthesiology
- Departments and Affiliations
- Hematology and Oncology
- Neurosurgery
- Public Health Sciences
- Anesthesiology
- Comprehensive Cancer Center
- Cardiovascular Sciences Center
- Hypertension and Vascular Research Center
Research
- Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population. Hu JJ, Urbanic JJ, Case LD, Takita C, Wright JL, Brown DR, Langefeld CD, Lively MO, Mitchell SE, Thakrar A, Bryant D, Baglan K, Strasser J, Baez-Diaz L, Lesser GJ, Shaw EG. J. Clin. Oncol. 2018 08; 36(24):2473-2482.
- Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas. Ramkissoon LA, Britt N, Guevara A, Whitt E, Severson E, Sathyan P, Gay L, Elvin J, Ross JS, Brown C, Stogner-Underwood K, Mott R, Kram D, Strowd R, Lesser GJ, Ramkissoon SH. Curr Treat Options Oncol. 2018 06; 19(8):41.
- Self-reported adherence and biomarker levels of CoQ10 and alpha-tocopherol. Vitolins MZ, Case LD, Rapp SR, Lively MO, Shaw EG, Naughton MJ, Giguere J, Lesser GJ. . 2018; 12:637-646.
- Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY. Neuro-oncology. 2018 03; 20(4):546-556.
- Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Rimkus TK, Carpenter RL, Sirkisoon S, Zhu D, Pasche BC, Chan MD, Lesser GJ, Tatter SB, Watabe K, Debinski W, Lo HW. Cancer Res. 2018 05; 78(10):2589-2600.
- A study on the effectiveness of four drugs (Vismodegib, GSK2256098, capivasertib, abemaciclib) against meningioma tumors
- A study of the drugs Vemurafenib and Cobimetinib in Treating Patients with BRAF Positive V600E Mutation Brain Tumor
- A study to identify therapies that improve overall survival for patients with Glioblastomas (GBM)